Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0D3OX
|
|||
Former ID |
DNC005460
|
|||
Drug Name |
N-[5-(2-Nitro-phenyl)-furan-2-carbonyl]-guanidine
|
|||
Synonyms |
CHEMBL425186; N-[5-(2-Nitro-phenyl)-furan-2-carbonyl]-guanidine
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C12H10N4O4
|
|||
Canonical SMILES |
C1=CC=C(C(=C1)C2=CC=C(O2)C(=O)N=C(N)N)[N+](=O)[O-]
|
|||
InChI |
1S/C12H10N4O4/c13-12(14)15-11(17)10-6-5-9(20-10)7-3-1-2-4-8(7)16(18)19/h1-6H,(H4,13,14,15,17)
|
|||
InChIKey |
KLPHIGVDYLBNDU-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Sodium/hydrogen exchanger 1 (SLC9A1) | Target Info | Inhibitor | [1] |
KEGG Pathway | cAMP signaling pathway | |||
Cardiac muscle contraction | ||||
Adrenergic signaling in cardiomyocytes | ||||
Regulation of actin cytoskeleton | ||||
Thyroid hormone signaling pathway | ||||
Salivary secretion | ||||
Gastric acid secretion | ||||
Pancreatic secretion | ||||
Bile secretion | ||||
Proteoglycans in cancer | ||||
Pathway Interaction Database | Endothelins | |||
RhoA signaling pathway | ||||
ErbB1 downstream signaling | ||||
Signaling mediated by p38-alpha and p38-beta | ||||
Reactome | Hyaluronan uptake and degradation | |||
WikiPathways | Regulation of Actin Cytoskeleton | |||
G Protein Signaling Pathways | ||||
Glycosaminoglycan metabolism | ||||
Osteoclast Signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | (5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J Med Chem. 2005 Apr 21;48(8):2882-91. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.